AstraZeneca has said it will invest $50bn in the US by 2030 in the latest funding pledge by an international drug company ahead of the potential imposition of tariffs on the sector by President Donald Trump.
The UK-based multinational will boost its manufacturing and research operations in America, including a “cornerstone” multibillion-dollar centre in Virginia to make crucial drug ingredients.
The pledge adds to a flurry of commitments by AstraZeneca’s US and European rivals, including a $50bn investment plan unveiled by Roche of Switzerland in April.
您已閱讀22%（557字），剩余78%（1994字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。